Antibody-based therapies are used to treat numerous diseases, from cancer to rheumatic disorders and multiple sclerosis.

University of Hawaiʻi Cancer Center researchers found in laboratory and animal models that when breast cancers stop ...

In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...

Researchers at Texas Biologics have made an important discovery that could improve treatment of human cytomegalovirus (HCMV), ...

Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour ...

MOG antibody-associated disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients ...

Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

For many antibodies, each antigen-binding site binds to only one antigen molecule during the antibody's lifetime in plasma. To increase the number of cycles of antigen binding and lysosomal ...